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Abstract Leflunomide is effective and well tolerated in the
treatment of rheumatoid arthritis (RA), however, data on its
use in early RA are scarce. This study seeks to evaluate
effectiveness and safety of leflunomide in the treatment of
early RA in daily practice. This prospective, open-label,
non-interventional, multi-center study was carried out over
24 weeks including adults with early RA (≤1 year since
diagnosis). Leflunomide treatment was according to label
instructions. Three hundred thirty-four patients were in-
cluded. Disease activity score in 28 joints (DAS28)
response (reduction in DAS28 of >1.2 or reduction of
>0.6 and a DAS28 of ≤5.1) was 71.9% at week12 and
84.6% at week 24. 25.0% of patients achieved clinical
remission (DAS28≤2.6). Most frequently reported adverse
drug reactions (ADR) were diarrhea (3.0%), nausea (2.4%),
hypertension (1.8%), and headache (1.5%). Serious ADR
were reported in four patients (1.2%). Leflunomide showed
the effectiveness which was to be expected from controlled
studies without revealing any new or hitherto unknown side
effects. Onset of action was quick and significant improve-
ment of disease was seen after 12 weeks of therapy and at
even higher rates after 24 weeks irrespective of the use of a
loading dose. Interestingly, the DAS28-remission rate
achieved was similar to the rate seen with methotrexate or
biologic therapy in other studies.
Keywords Daily practice.DAS28 response.Early
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Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory
systemic disease which primarily affects the joints and
often leads to joint destruction resulting in functional
impairment and invalidity.
Irreversible joint damage occurs early in the course of
the disease and it is now widely accepted that early
treatment of RA is associated with a better outcome [1–4].
It has been shown in several clinical trials that the
disease-modifying anti-rheumatic drug (DMARD), lefluno-
mide, is effective and well tolerated in the treatment of RA.
Its beneficial effects showed in high American College of
Rheumatology (ACR) response rates and comprised retar-
dation of radiographic progression as well as improvement
of physical function and health-related quality of life [5].
Symptoms of disease improved within a month of starting
treatment and improvement was maintained in the long-
term. Via its effect on Tcells, leflunomide addresses several
levels of the inflammatory cascade and has anti-
proliferative, anti-inflammatory, and anti-destructive abili-
ties [6–8]. This special mode of action together with its
rapid onset of action makes it a promising drug also in the
treatment of early RA where the prevention of irreversible
structural damage is an important goal. A subgroup analysis
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of leflunomide in early (<2 years of disease duration) and
late disease (>2 years of disease duration) in contrast to
sulfasalazine which seems to have better efficacy in later
disease stages [8]. However, data on leflunomide in the
treatment of early RA are scarce.
The aim of this non-interventional study on leflunomide
was to provide information on the effectiveness and
tolerability of leflunomide in the treatment of early RA
under routine care conditions.
Materials and methods
Study design
This prospective, open-label, non-interventional, multi-
center observational study was carried out between May
2006 and September 2007 by rheumatologists throughout
Germany. The study comprised for each patient a docu-
mentation period of 24 weeks including visits at Baseline,
after 12 weeks (interim visit) and after 24 weeks (final
visit). Due to the non-interventional study design, IRB
review and patient informed consent were not necessary at
the time of the study.
Patient population
Adult patients with early rheumatoid arthritis (defined by
a maximum disease duration of 1 year since diagnosis)
were eligible for inclusion if the investigator was
convinced that they might profit from treatment with
leflunomide and if they did not show any contraindica-
tions. The physician’s decision for leflunomide treatment
was based on the patient’s condition and independent of
study documentation.
Treatment
Dosing recommendations were according to the current
summary of product characteristics of Arava® (loading
dose: leflunomide 100 mg per day for 3 days; maintenance
dose: leflunomide 10 to 20 mg per day).
Statistical analysis
The primary effectiveness parameter was the disease activity
score 28 (DAS28) response rate after 24 weeks. The DAS28
was calculated based on the swollen joint count (SJC), tender
joint count (TJC), erythrocyte sedimentation rate (ESR), and
the patient’s global health assessment on a visual analogue
scale (VAS). DAS28 response was defined as good or
moderate response according to the EULAR criteria [9].
The response rate was calculated including exact 95%
confidence limits for binomial proportion using the F
distribution method by Collet. The influence of glucocorti-
coids and MTX as concomitant medication on the effec-
tiveness of therapy was evaluated by an analysis of
covariance. This model included the change in DAS28
between start and final visit as dependent variable, baseline
values as covariate and the use of glucocorticoids and MTX
as two independent factors (no interaction was included
into the model).
Secondary effectiveness parameters were the DAS28
response rate after 12 weeks, changes in DAS28, TJC, SJC,
ESR, and C-reactive protein (CRP) during 24 weeks,
changes in the health assessment questionnaire-disability
index (HAQ-DI) [10] and changes in pain (assessed by
VAS). The safety evaluation comprised changes in vital
signs and laboratory parameters as well as the documenta-
tion/reporting of adverse events.
P values of all statistical tests were of exploratory
character. Missing values were not replaced.
Results
Patient disposition
A total of 174 centers throughout Germany contributed data
of 334 patients. All of these patients had received
leflunomide and were evaluated for safety. Twenty-six
patients in whom RA had been diagnosed more than 1 year
before enrollment were excluded from the effectiveness
population which therefore comprised 308 patients.
Analysis of DAS28 response only considered patients with
evaluable DAS28 score at baseline and at least one visit after
baseline (response analysis population=276 patients).
Demographic and other baseline characteristics
In the mean 9.0 ± 22.3 (median: 3.0, 99% percentile: 131.0)
months had passed between the occurrence of first RA
symptoms and diagnosis and 16.3 ± 28.0 (median: 9.0, 99%
percentile: 177.0) months between the occurrence of first
symptoms and start of documentation. Demographic and
other baseline characteristics are summarized in Table 1.
Treatment and observation period
Patients (57.2%) received the recommended loading dose
of 100 mg leflunomide/day. The maintenance dose was
20 mg leflunomide/day in 91.6% of patients and 10 mg
leflunomide/day in 8.4% of patients. In the majority of
patients the dose remained unchanged during the observa-
tion period. Patients (61.7%) were concomitantly treated
914 Clin Rheumatol (2010) 29:913–920with corticosteroids. In 27.5% of patients additional
DMARDs, most frequently methotrexate (22.2%), were
used, although not recommended.
Treatment with leflunomide was discontinued in 11.1% of
patients. Reasons included adverse event (6.3%), patient’s
request (3.3%), and insufficient therapeutic effect (3.0%).
The patients were observed for an average of
25.5± 6.0 weeks.
DAS28 response
A high response rate was achieved under leflunomide with
84.6% of patients showing good or moderate DAS28
response after 24 weeks.
A considerable rate of responders was already seen after
12 weeks where 71.9% of patients met the criteria of
DAS28 response. Response at both time points was
independent of the use of a loading dose (response rate no
loading dose versus loading dose after 12 weeks, 68.2%
versus 74.5%, and after 24 weeks, 82.4% versus 86.2%).
An overview of the individual DAS28 response categories
is given in Table 2.
Analysis of the DAS28 response rate after 24 weeks
differentiated by whether or not the patients had received
pre-treatment with other DMARD(s) showed no influence
of this factor. However, when the individual response
categories were examined it became obvious that the rate
of patients with good response (DAS28≤3.2 and reduction
by >1.2) was clearly greater in DMARD-naïve patients
compared to those who had received DMARD pre-
treatment (44.5% versus 25.0%; see also Fig. 1).
Concomitant treatment with corticosteroids or MTX did
not have an effect on DAS28-response (p=0.86 for CS and
p=0.27 for MTX)
Table 2 DAS28 response rates after 12 and 24 weeks of leflunomide treatment (response analysis population)
DAS28 response Week 12 Week 24
N
a=260 N
a=254
n (%) 95% CI n (%) 95% CI
Good or moderate response 187 (71.9) 66.0–77.3 215 (84.6) 79.6–88.9
Good response 52 (20.0) 15.3–25.4 92 (36.2) 30.3–42.5
Moderate response 135 (51.9) 45.7–58.1 123 (48.4) 42.1–54.8
Insufficient response 73 (28.1) 22.7–34.0 39 (15.4) 11.2–20.4
CI confidence interval, DAS disease activity score, Good response DAS28 score ≤3.2 plus improvement of >1.2, Moderate response DAS 28
score ≤3.2 plus improvement of >0.6 to ≤1.2 or DAS 28 score >3.2 to ≤5.1 plus improvement of >0.6 or DAS 28 score >5.1 plus improvement of
>1.2, Insufficient response improvement in DAS28 score of ≤0.6 or improvement of >0.6 to ≤1.2 plus DAS28 score >5.1
aPatients with evaluable data
Age (years, mean±SD) 55.8 ± 13.2
Female (n,% ) 243 (73.0)
Time since RA diagnosis, months, mean±SD (median) 7.5 ± 15.8 (4.0)
Rheumatoid factor, n (%)
Positive 242 (73.1)
Negative 89 (26.9)
Anti-CCP (n,% )
Positive 143 (60.9)
Negative 92 (39.1)
Rheumatoid nodules (n, %) 38 (11.6)
Joint erosion (n,% )
Yes 139 (45.6)
No 166 (54.4)
DMARD-naïve (n, %) 174 (52.1)
DMARD pre-treatment (n, %) 160 (47.9)
Methotrexate pre-treatment 140 (41.9)
Corticosteroid injection within the last 30 days (n, %) 34 (12.2)
Table 1 Demographic and oth-
er baseline characteristics (safety
population)
Percentages are adjusted relative
frequencies, i.e., missing values
are not considered
CCP cyclic citrullinated peptide,
DMARD disease-modifying
anti-rheumatic drug, RA rheu-
matoid arthritis, SD standard
deviation
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As illustrated by Fig. 2, disease activity improved markedly
during the course of the study with the most pronounced
improvement already visible after 12 weeks of treatment
and a further decrease in disease activity by week 24. The
proportion of patients with high disease activity (DAS28
score>5.1–10) was clearly reduced from 71.0% at baseline
to 13.8% at the final visit while the rates of clinical
remission (0–2.6), low disease activity (>2.6–3.2) and
moderate disease activity (>3.2–5.1) showed an increase.
After 24 weeks of treatment 25.0% of patients were in
clinical remission.
Accordingly, mean DAS28 score declined from 5.7±1.2
at baseline to 4.2±1.4 after 12 weeks and 3.7±1.4 at the
final visit (see also Fig. 3). Endpoint analysis
1 of the
difference between final visit and baseline showed a mean
reduction of −2.1±1.6 (p<0.001, Wilcoxon signed rank
test).
TJC, SJC, erythrocyte sedimentation rate, and CRP
The results described above for the DAS28 score were
reflected in the individual components TJC, SJC, and ESR
as well as in CRP (as summarized in Table 3). The
objective parameters number of swollen joints, ESR, and
CRP as well as the subjective component number of tender
joints had markedly improved by week12 and showed a
further decrease by week 24.
HAQ-DI and -pain scale
As shown in Table 4 the patient-reported outcome measures
HAQ-DI and pain both showed considerable improvement
during treatment with leflunomide which again was already
observed at week12.
Safety
Adverse events were documented for 36 patients (10.8%),
which were considered by the investigator as being drug-
related in 32 patients (9.6%). Most frequently reported
adverse drug reactions (ADR) were diarrhea (3.0%),
nausea (2.4%), hypertension (1.8%), and headache
(1.5%). Serious ADR were reported in four patients
(1.2%) and comprised hypertension, pneumonia, produc-
tive cough, pyrexia, erysipelas, vomiting nausea, and
hypotension. All of these patients recovered completely.
Four cases of unexpected ADR were hypotension,
dyspnea, dry throat, and glossodynia.
In addition to the above-mentioned adverse events,
elevations in liver transaminases (as described in the
summary of product characteristics) from normal to ≥2×
upper limit of normal were noted in seven patients (6.6%;
N=106 with normal value at baseline) for alanine amino-
transferase and in two patients (5.1%; N=39 with normal
value at baseline) for aspartate aminotransferase
2. Increases
in transaminases from normal values to values ≥3× upper
limit of normal were not seen.
2 Since normal range depends on gender, one patient with missing
data on gender could not be taken into account.
86.6 85.6
R
e
s
p
o
n
s
e
 
r
a
t
e
 
(
%
)
0
20
40
60
80
100
0
20
40
60
80
100
DAS28 response 
good response 
moderate response 
insufficient response 
No pre-treatment
with DMARDs
(N=146)
Pre-treatment
with DMARDs
(N=108)
85.6
83.3
P
r
o
p
o
r
t
i
o
n
 
o
f
 
p
a
t
i
e
n
t
s
 
(
%
)
No pre-treatment
with DMARDs
(N=146)
Pre-treatment
with DMARDs
(N=108)
  DAS28 response   DAS28 response subcategories
Fig. 1 DAS28 response rate
after 24 weeks by DMARD
pre-treatment (response popula-
tion). DAS disease activity score
1 Including only patients with data both for baseline and final
visit (N=254).
916 Clin Rheumatol (2010) 29:913–920Neither for vital signs nor for body weight was relevant
changes observed under treatment.
Discussion
RA patients with disease duration ≤1 year since diagnosis
treated by rheumatologists well distributed all over Ger-
many were included in this non-interventional study,
16 months had passed between the occurrence of first
symptoms and enrollment, thus the results can be consid-
ered as being representative for early RA patients under
specialist care. Also with regard to age and gender, the
patients represented a typical RA population with a mean
age of 56 years and the majority of patients being women.
Analysis of the time between first RA symptoms and
diagnosis shows that a considerable period can elapse
before a final diagnosis is established. Whether this delay is
caused by a long referral time from the general practitioner
to the specialist can only be assumed. Given the importance
of early and effective treatment of RA, optimizing the time
to diagnosis seems necessary.
With respect to the inflammatory markers CRP and ESR
and the measures of disease activity DAS28, TJC, and SJC,
disease characteristics at baseline were overall comparable
to those described for other early RA study populations [11,
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inclusion and exclusion criteria and these are often stricter
in clinical studies where, in contrast to our non-
interventional study, joint erosions or specific minimum
tender or swollen joint counts may be required and patients
might therefore present with a more severe illness.
Despite the relatively short disease duration in our study,
joint erosions were already present in 45.6% of patients,
again indicating the early occurrence of joint damage in the
course of the disease.
As shown by the high DAS28 response rate, patients
with early RA clearly profited from leflunomide treatment.
Corresponding to the rapid onset of action of leflunomide
described in the pivotal phase III study (US301) [6] where a
positive effect regarding ACR20 response was seen after
1 month, a considerable DAS28 response rate of 71.9% was
already seen at the interim visit after 12 weeks which
further increased to 84.6% after 24 weeks. The high DAS28
response rate in our study at least matches the good
response rates reported previously for leflunomide; in fact
it is even higher. Dougados et al. found 69.6% of DAS28
responders after 24 weeks of treatment in the open phase of
the RELIEF study [13]. However, disease characteristics in
RELIEF at baseline with a longer disease duration (7 years)
and a higher disease activity (mean DAS28: 6.3; high
disease activity in 86.5%) were markedly different from
those in our study. Furthermore, a clearly higher proportion
of patients had received DMARD pre-treatment. A further
open-label study by Nguyen et al. [14] (disease duration
9.7 years; high disease activity at baseline in 63.0%)
reported 61.8% of DAS28 responders at 6 months. The
short disease duration together with the fact that approxi-
mately 50% of the patients were DMARD-naïve could have
added to the higher response rates observed in our study.
However, DMARD pre-treatment on its own had no effect
on the overall response rate although more “good respond-
ers” were seen in DMARD-naïve patients. The fact that
anti-CCP which is known to predict an aggressive disease
course with an unfavorable outcome [15] was only found in
60.9% of the patients (N=235 patients with data available)
might also have contributed. However, a subgroup analysis
revealed no differences in DAS28-response in anti-CCP
positive and negative patients.
A further subgroup analysis evaluating a possible
influence of the administration of the loading dose on
DAS28-response resulted in similar response rates in
patients who had received a loading dose and those who
had not. This finding adds new elements to the ongoing
Table 3 Course of tender joint count, swollen joint count, erythrocyte sedimentation rate, and C-reactive protein (effectiveness population)
TJC (mean±SD) SJC (mean±SD) ESR (mm/h, mean±SD) CRP (mg/L, mean±SD)
Baseline 10.1 ± 6.6 8.1 ± 5.7 39.7 ± 22.4 37.7 ± 80.5
Week 12 5.7 ± 5.4 4.1 ± 4.2 26.1 ± 19.4 Not done
Week 24 3.9 ± 4.7 2.6 ± 3.6 23.2 ± 17.2 13.2 ± 22.4
Difference week24–baseline
a -6.6 ± 6.6 -5.8 ± 5.6 -17.7 ± 23.1 -26.8 ± 70.6
P value for changes
b <0.001 <0.001 <0.001 <0.001
CRP C-reactive protein, ESR erythrocyte sedimentation rate, SD standard deviation, SJC swollen joint count, TJC tender joint count
aEndpoint analysis, i.e., only patients considered with data both for baseline and week 24
bWilcoxon signed rank test
Table 4 Course of HAQ-DI and pain (effectiveness population)
HAQ-DI HAQ-pain scale
c (mm)
(range 0–3) (range 0–100)
Mean±SD Mean±SD
Baseline 1.37 ± 0.7 60.3 ± 21.2
Week 12 0.95 ± 0.69 39.4 ± 21.4
Week 24 0.82 ± 0.66 29.0 ± 20.0
Difference week 24–baseline
a −0.56 ± 0.62 −31.6 ± 27.3
P value for changes
b <0.001 <0.001
HAQ-DI health assessment questionnaire-disability index, SD standard deviation
aEndpoint analysis, i.e., only patients considered with data both for baseline and week 24
bWilcoxon signed rank test
cCurrent pain on day of assessment in contrast to average pain over last 7 days as in original HAQ
918 Clin Rheumatol (2010) 29:913–920discussion about the benefit/risk of the loading dose
regimen for leflunomide, but since this is coming from a
subgroup analysis from an observational study a conclusive
answer is not possible and requires further clinical study.
The fact that concomitant corticosteroids and MTX had
no influence on the DAS28-response reflects the naturalis-
tic setting of this study and can be attributed to the patient
channeling which takes place in daily clinical practice.
Corresponding to the high response rate all of the further
parameters analyzed in this study showed great improve-
ment under treatment. Clinical remission, defined as
DAS28≤2.6, was reached in 25% of patients. A similar
remission rate (24.4%) was seen in an open-label study
with leflunomide in DMARD-naïve patients with early RA
[16]. The remission rate in our study furthermore corre-
sponds to the rates observed for anti-TNF-alpha and MTX
monotherapy: In the PREMIER study with early RA
patients who, however, presented with a more severe
disease (higher values for SJC, TJC, HAQ-DI, and mean
DAS28) DAS28 remission rates at year1 were 23.0% for
adalimumab and 21.0% for MTX [17]. The remission rate
for MTX monotherapy in the COMET study was 28% at
week52 [18].
Reductions in mean DAS28, SJC, TJC, pain, and ESR at
3 months were comparable to those of an observational
study with leflunomide on RA patients with longer disease
duration [19]. Compared to the results for the subgroup of
DMARD-naïve patients with early RA after 6 months of
leflunomide treatment in the phase III study MN301,
improvement with regard to pain in our study was very
similar, while reductions in SJC and TJC were smaller [20].
Results obtained for the HAQ-DI underlined the benefit the
patients gained in physical function by leflunomide
treatment. A mean reduction by 0.56 with a minimum
difference of 0.22 considered as clinically important [21]
showed that functional ability was meaningfully improved
under treatment. A comparable outcome was observed in
the US301 phase III study [6], where interestingly, with
markedly higher swollen and tender joint counts, the HAQ-
DI score at baseline was quite similar to the one in our
study.
The results of the safety evaluation were consistent with
the known safety profile of leflunomide and no new safety
risks were observed.
Conclusions
Leflunomide showed the effectiveness which was found in
controlled studies without revealing any new or hitherto
unknown side effects. Onset of action was quick and
significant improvement of disease was seen after 12 weeks
of therapy and at even higher rates after 24 weeks.
Interestingly, the remission rate achieved was similar to
the rate seen with methotrexate or biologic therapy in other
studies. This outlines the importance of the potential benefit
of leflunomide in the treatment of early RA patients in
routine rheumatology setting.
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